112 results on '"Cottu, Paul H."'
Search Results
2. Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy
3. Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis
4. Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.
5. A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design
6. Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study
7. Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
8. Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France
9. Abstract P2-13-27: Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study
10. Abstract P1-18-19: Long term results with everolimus in advanced hormone receptor positive breast cancer in a multicenter national real world observational study (ESME)
11. Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program.
12. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients
13. Abstract OT-38-01: MEDEA: A randomized trial of weight loss to reduce cancer-related fatigue (CRF) among overweight and obese breast cancer (BC) patients
14. Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
15. Questions prompt lists used by palliative care teams help trigger discussions on prognosis and end-of-life issues with advanced cancer patients.
16. Tolerance of concurrent CDK inhibitor and radiation therapy in metastatic breast cancer patients.
17. Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).
18. High dose chemotherapy with stem-cell transplantation in a metastatic medulloblastoma in an adult: a case report and review of the literature
19. A MULTISTEP RANDOMIZED PHASE II/III TRIAL COMPARING OXALIPLATIN (OXA)+ 5 FLUOROURACIL (FU) TO VINORELBINE (VIN)+FU (FUN) AFTER TAXANE (T)/ANTHRACYCLINE (A) FAILURE IN ADVANCED/METASTATIC BREAST CANCER (MBC) PATIENTS (PTS): 245
20. Dose-dense docetaxel and epirubicine combination in advanced breast cancer: Preliminary results.
21. Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study
22. Pooled analysis of onapristone extended release (ONA ER) in metastatic cancer patients (pts): A review of liver safety.
23. Prediction of treatment (tx)-induced fatigue in breast cancer (BC) patients (pts) using machine learning on genome-wide association (GWAS) data in the prospective CANTO cohort.
24. High temporal variability of clinical side effects with and without adjuvant chemotherapy in 4,684 early breast cancer patients in the CANTO trial.
25. mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with everolimus-exemestan: Results from the SAFIRTOR study.
26. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).
27. Return to work after breast cancer: Comprehensive longitudinal analyses of its determinants.
28. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
29. A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer
30. Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.
31. Use of everolimus in advanced hormone receptor–positive metastatic breast cancer in a multicenter national observational study.
32. Pharmacogenetics revisits bevacizumab in breast cancer patients: An ancillary analysis of the UCBG trial COMET—A French multicentric prospective study from R&D UNICANCER.
33. UNICANCER: Prospective cohort study of treatment related chronic toxicities in patients with localized breast cancer (CANTO).
34. Efficacy and long-term safety with bevacizumab included in neoadjuvant and adjuvant therapies in patients with advanced ovarian cancer: Results of the ANTHALYA trial.
35. Assessment of multiple endocrine therapies for metastatic breast cancer in a multicenter national observational study.
36. Les traitements médicaux néoadjuvants des cancers du sein luminaux en 2016
37. Validation of a population pharmacokinetic (PPK) model for onapristone (ONA) in patients (pts) with cancer: Analysis of 2 clinical trials.
38. Systematic biopsy of the first metastatic event in breast cancer: Results from ESOPE—A prospective multicenter trial.
39. Prospective multicenter study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with early stage breast cancer: which patients are the best candidates?
40. Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.
41. Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.
42. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
43. Correlation of baseline clinical characteristics and laparoscopic extent of carcinomatosis of women with initially unresectable ovarian, tubal or peritoneal adenocarcinoma, in ANTHALYA study: A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant.
44. Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: Efficacy and biomarker results of a dose-escalation phase 1 study.
45. Safety and pharmacokinetic (PK) results from phase 1 of an ongoing phase 1-2 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.
46. Phase 2 clinical study of onapristone (ONA) in patients (pts) with uterine endometrioid adenocarcinoma (EC) expressing the activated progesterone receptor (APRpos).
47. Abstract P5-19-26: Efficacy and tolerance of everolimus in 123 consecutive very advanced luminal breast cancer patients. A multicenter retrospective study
48. Abstract OT3-2-06: NEOPAL: A randomized phase II study comparing RCB response to neoadjuvant chemotherapy or letrozole-palbociclib in PAM50 defined postmenopausal luminal breast cancer
49. A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.
50. A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.